After a Phase III new antibiotic program disappointment last year, Allschwil, Switzerland-based Polyphor Ltd. is refocusing its research efforts on a potential first-in-class immuno-oncology compound, while becoming a leaner organization with the loss of around 17 positions.
With current funds, Polyphor’s cash runway will last until the end of the first quarter of 2021, executives at the Swiss SIX Exchange-quoted company told an analyst briefing on 20...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?